MARKET

PROG

PROG

PROGENITY, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.250
0.000
0.00%
Pre Market: 3.200 -0.05 -1.54% 06:42 06/23 EDT
OPEN
3.329
PREV CLOSE
3.250
HIGH
3.380
LOW
3.110
VOLUME
10
TURNOVER
--
52 WEEK HIGH
13.95
52 WEEK LOW
2.040
MARKET CAP
146.78M
P/E (TTM)
-0.3531
1D
5D
1M
3M
1Y
5Y
(PROG) Long Term Investor Alert: Johnson Fistel Investigates Progenity; Should Management be Held Accountable for Investors Losses?
SAN DIEGO, June 19, 2021 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating potential claims on behalf of Progenity, Inc. (NASDAQ: PROG) against certain current and former officers and directors. In June 2020, Progenity completed its initial public o...
GlobeNewswire · 4d ago
BRIEF-Progenity Says Selling Stockholders Offering On A Resale Basis 32.4 Million Shares Of Common Stock
reuters.com · 5d ago
BRIEF-Progenity Establishes Inflammatory Bowel Disease Clinical Advisory Board
reuters.com · 5d ago
Implied Volatility Surging for Progenity (PROG) Stock Options
Zacks.com · 06/15 12:30
Progenity to Participate in the Raymond James 2021 Human Health Innovation Conference
Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced that Harry Stylli, PhD, CEO, chairman of the board, and co-founder of Progenity, will participate in a fireside chat at the virtual Raymond James 2021 Human Health Innovat...
GlobeNewswire · 06/15 12:06
22 Stocks Moving in Monday's Pre-Market Session
Gainers MediaCo Holding Inc. (NASDAQ: MDIA) rose 73.4% to $6.66 in pre-market trading. MediaCo, last week, named Rahsan-Rahsan Lindsay as Chief Executive Officer, effective July 1, 2021.
Benzinga · 06/14 11:01
64 Biggest Movers From Friday
Gainers Kanzhun Limited (NASDAQ: BZ) shares climbed 95.8% to close at $37.20 on Friday after the company priced its IPO at $19 per share.
Benzinga · 06/14 09:04
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers
Benzinga · 06/11 20:32
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PROG. Analyze the recent business situations of PROGENITY, INC. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PROG stock price target is 4.750 with a high estimate of 12.00 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 54
Institutional Holdings: 43.20M
% Owned: 95.66%
Shares Outstanding: 45.16M
TypeInstitutionsShares
Increased
21
1.75M
New
10
4.58M
Decreased
10
185.95K
Sold Out
11
381.38K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+1.15%
Healthcare Equipment & Supplies
+0.78%
Key Executives
Chairman/Chief Executive Officer/Director
Harry Stylli
Chief Financial Officer
Eric d'Esparbes
Chief Financial Officer/Primary Contact
Eric d Esparbes
Chief Operating Officer
Damon Silvestry
Senior Vice President/Director of Sales
George Gianakopoulos
Chief Information Officer
Troy Seelye
Chief Scientific Officer
Matthew Cooper
Chief Compliance Officer
Hutan Hashemi
General Counsel/Secretary
Clarke Neumann
Other
Sami Shihabi
Lead Director
Jeffrey Alter
Independent Director
John Bigalke
Independent Director
Jeffrey Ferrell
Independent Director
Brian Kotzin
Independent Director
Samuel Nussbaum
Independent Director
Lynne Powell
No Data
About PROG
Progenity, Inc. is a biotechnology company. The Company is engaged in developing and commercializing molecular testing products and precision medicine. It applies multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics, to its molecular testing products and to the development of a suite of investigational ingestible devices and drug/device combinations designed to provide precise diagnostic sampling and drug delivery solutions. It offers integrated molecular tests and end-to-end support services that enable physicians to incorporate genetic testing into their office workflow and enables in ordering multiple tests from one source. The Company’s molecular tests are: Innatal Prenatal Screen, Preparent Carrier Test, Riscover Hereditary Cancer Test, Resura Prenatal Test for Monogenic Disease, and Anatomic and Molecular Pathology Tests. It is also developing an ingestible capsule platform designed to help diagnose and treat gastrointestinal (GI) disorders.

Webull offers kinds of Progenity Inc stock information, including NASDAQ:PROG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PROG stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PROG stock methods without spending real money on the virtual paper trading platform.